Urinary frequency
Also known as: Urine, Urinary, Urinate
Methodology & AI Transparency ⓘ
Urinary frequency Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Prostate (BPH), Bladder & Urinary Tract diagnostic criteria (R35.0), workup for Urinary frequency (also termed Urine or Urinary) integrates IPSS symptom scoring [Urinary frequency R35.0] with evidence-graded therapy tailored to IPSS Urinary Symptom in Urinary frequency (R35.0: Score) response.
- 2 Real-world patient consensus: Synonyms for Urinary frequency (R35.0): Urine, Urinary, Urinate (Urology & Prostate).
- 3 Typical cash cost range: Primary evaluation for Urinary frequency incorporates IPSS symptom scoring [Urinary frequency R35.0] and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Urinary frequency monitoring tracks IPSS Urinary Symptom in Urinary frequency (R35.0: Score) toward 0 – 7 (mild symptoms) (R35.0).
Ask our AI Specialists anything about Urinary frequency
What Is Urinary frequency?
Under Prostate (BPH), Bladder & Urinary Tract diagnostic criteria (R35.0), workup for Urinary frequency (also termed Urine or Urinary) integrates IPSS symptom scoring [Urinary frequency R35.0] with evidence-graded therapy tailored to IPSS Urinary Symptom in Urinary frequency (R35.0: Score) response.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Urinary frequency (R35.0) center on prostatic fibromuscular stromal in Urinary frequency (R35.0: hyperplasia). targeted urology & prostate interventions aim to normalize IPSS Urinary Symptom in Urinary frequency (R35.0: Score).
Common Symptoms & Clinical Signs
- • Presentation of Urinary frequency (R35.0): weak, hesitant, or in Urinary frequency (R35.0: intermittent urinary stream)
- • Secondary Urinary frequency clinical sign: waking two or in Urinary frequency (R35.0: more times nightly)
- • Symptom flares in Urinary frequency correlating with IPSS Urinary Symptom in Urinary frequency (R35.0: Score) deviation outside 0 – 7 (mild symptoms) (R35.0)
- • Functional urology & prostate impact requiring IPSS symptom scoring [Urinary frequency R35.0] evaluation (R35.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Urinary frequency Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R35.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Prostate (BPH), Bladder & Urinary Tract | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: IPSS Urinary Symptom in Urinary frequency (R35.0: Score) | 0 – 7 (mild symptoms) (R35.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urinalysis & Post-Void in Urinary frequency (R35.0: Residual (PVR)) | Negative leukocyte/nitrite; PVR < 50 mL (R35.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Total PSA & in Urinary frequency (R35.0: Serum Creatinine/eGFR) | Age-specific PSA; eGFR > 75 mL/min (R35.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Urinary frequency
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Phenazopyridine Hydrochloride Uqora Maximum Uti Pain Relief, Urinary Pain Relief • RxCUI 1094104 | Over-the-Counter Clinical Monograph | 92% | $0.1748 | $ 15.58 /mo |
| Flavoxate Hydrochloride Urispas • RxCUI 1095229 | Cholinergic Muscarinic Antagonist | 76% | $0.3821 | $ 15.84 /mo |
| Marstacimab-Hncq Hympavzi • RxCUI 2697139 | FDA Prescription Therapeutic Agent | 74% | $0.6400 | $ 34.42 /mo |
| Mitoxantrone Mitoxantrone Generic • RxCUI 197989 | Topoisomerase Inhibitor | 93% | $0.3500 | $ 22.68 /mo |
| Emicizumab Hemlibra • RxCUI 1989799 | FDA Prescription Therapeutic Agent | 88% | $2.1400 | $ 95.17 /mo |
| Etomidate Injection, Solution Etomidate Injection, Solution Generic • RxCUI 1654006 | General Anesthetic | 90% | $2.7500 | $ 119.88 /mo |
| Droxia (Hydroxyurea) Droxia • RxCUI 200342 | Antimetabolite | 86% | $0.7291 | $ 61.00 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Urinary frequency)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Testosterone Replacement Therapy on Lower Urinary Tract: What a 2,029-Participant Study Found In this meta-analysis of 14 clinical trials of TRT for LOH, the change in IPSS was similar among men receiving TRT versus placebo, suggesting that TRT treatment does not worsen LUTS among men with LOH. European urology • 2016-06-15 • Meta-Analysis | N = 2,029 | 99/100 | PMID 26874809 ↗ |
| New Insights on Urinary tract infections in patients with diabetes treated with: What a 3,152-Participant Study Found Treatment of type 2 diabetes with once-daily dapagliflozin 5 or 10mg is accompanied by a slightly increased risk of urinary tract infection. Journal of diabetes and its complications • 2013-01-15 • Meta-Analysis | N = 3,152 | 99/100 | PMID 23849632 ↗ |
| New Insights on Effect of testosterone replacement therapy on lower urinary tract: What a 2,453-Participant Study Found The results demonstrate that TRT does not worsen LUTS regardless of the administration route. Journal of evidence-based medicine • 2024-09-15 • Meta-Analysis | N = 2,453 | 99/100 | PMID 39004879 ↗ |
| New Insights on Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction: What a 1,075-Participant Study Found Low TT levels at baseline did not negatively influence response to tadalafil in men of advancing age with concomitant lower urinary tract symptoms and benign prostatic hyperplasia and erectile dysfunction. The journal of sexual medicine • 2016-05-15 • Randomized Controlled Trial | N = 1,075 | 96/100 | PMID 27017071 ↗ |
| New Insights on Sulopenem versus Amoxicillin/Clavulanate for the Treatment of Uncomplicated: What a 2,222-Participant Study Found Sulopenem was noninferior to amoxicillin/clavulanate for the treatment of adult women with uncomplicated urinary tract infection, but was associated with more frequent mild side effects. NEJM evidence • 2025-07-15 • Phase III Randomized Trial | N = 2,222 | 96/100 | PMID 40552968 ↗ |
Urinary frequency Patient Community & “People Like Me” Threads
Filter Urinary frequency community threads and patient logs by age, biological sex, dosage, and treatment duration.